(Q33591450)

28 July 2017

1 reference

title

Bile acid abnormalities in cholestatic liver diseases (English)

1 reference

28 July 2017

Salen G

1

1 reference

PubMed ID

10198784

28 July 2017

Batta AK

series ordinal

2

1 reference

28 July 2017

1 March 1999

1 reference

Gastroenterology Clinics of North America

28 July 2017

1 reference

28 July 2017

28

1 reference

28 July 2017

1

1 reference

28 July 2017

173-193

1 reference

Surgical management of Caroli's disease involving both lobes of the liver.

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Bile acid metabolism in cirrhotic liver tissue--altered synthesis and impaired hepatic secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Deficient interleukin-2 responsiveness of T lymphocytes from patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

1 reference

7 January 2021

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Randomized trial of chlorambucil for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursocholic acid: bile acid and bile lipid dose response and clinical studies in patients with gall stones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

NIH conference: Primary biliary cirrhosis: a model autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid therapy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Medical approaches to primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Urinary excretion of bile alcohols in normal children and patients with alpha 1-antitrypsin deficiency during development of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Current concepts. Primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Byler's disease: fatal intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

The identification of urinary bile alcohols by gas chromatography-mass spectrometry in patients with liver disease and in healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Efficacy of liver transplantation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

1 reference

7 January 2021

Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Successful treatment of Caroli's disease by hepatic resection. Report of six patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Liver disease and bile duct abnormalities in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Bile acids, liver injury, and liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis. Clinical and histologic follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Hepatic injury induced by bile salts: correlation between biochemical and morphological events

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Primary biliary cirrhosis, dark adaptometry, electro-oculography, and vitamin A state

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Orthotopic liver transplantation for Byler disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Evolution of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: a comparison of complications and outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Bile acid profiles in siblings with progressive intrahepatic cholestasis: absence of biliary chenodeoxycholate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Metabolism of ursocholic acid in humans: conversion of ursocholic acid to deoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Primary biliary cirrhosis: an epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Primary sclerosing cholangitis. A study of forty-two cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

Immunomodulatory effects of ursodeoxycholic acid on immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8553%2805%2970049-2

7 January 2021

10.1016/S0889-8553(05)70049-2

Identifiers

DOI

1 reference

release_u56txkc4onbbhjtulmtyxeyexi

28 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u56txkc4onbbhjtulmtyxeyexi

24 November 2022

mapped directly with Wikidata item

PubMed ID

10198784

1 reference

PubMed ID

10198784